Core Viewpoint - Weis Markets Inc. is under investigation for potential violations of federal securities laws following the announcement of restated financial statements due to inventory misstatements [1][2]. Group 1: Financial Disclosure - On February 26, 2026, Weis Markets disclosed that it would restate certain financial statements, including audited financial statements for fiscal years 2022 through 2024 and interim financial statements for 2025, due to inaccurately recorded and overstated inventory [2]. - The company announced a delay in filing its 2025 Annual Report on Form 10-K while it completes the review and restatement process [2]. Group 2: Market Reaction - Following the announcement of the restatement, Weis Markets' share price fell by $5.12, or approximately 7.16%, from $71.51 on February 25, 2026, to close at $66.39 on February 26, 2026 [2].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. - The investigation is prompted by significant changes in the company's financial performance following its IPO [3]. Group 3: Financial Performance and Stock Impact - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 per share [4]. - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of the company's new home-lending business [4].

.@CFTC Joins SEC to Clarify the Application of Federal Securities Laws to Crypto Assets: https://t.co/xuoRu9Abal ...

Core Viewpoint - Lowey Dannenberg P.C. is investigating Babcock & Wilcox Enterprises Inc. for potential violations of federal securities laws following concerns raised by a short seller regarding the company's $2.4 billion contract with Base Electron [1][2]. Group 1: Investigation Details - The investigation is prompted by a report from a short seller questioning the viability of Babcock & Wilcox's recently announced $2.4 billion contract [2]. - The report alleges that the deal with Base Electron may not materialize and highlights connections between Base Electron and B&W shareholder B. Riley Financial [2]. - Babcock & Wilcox's description of Base Electron as a "subsidiary" conflicts with Applied Digital's characterization of it as an "independent" company in which it owns 10% equity [2]. Group 2: Market Reaction - Following the publication of the short seller's report, Babcock & Wilcox shares experienced a decline of 9.6% [2].

Core Viewpoint - Encompass Health Corporation is under investigation for potential violations of federal securities laws following allegations of subpar performance in safety measures at its for-profit hospitals [1][2]. Group 1: Investigation Details - Lowey Dannenberg P.C. is leading the investigation into Encompass Health Corporation for possible breaches of federal securities laws [1]. - The investigation is prompted by a New York Times article that reported on the company's below-average performance in key safety measures, including high rates of preventable readmissions [2]. Group 2: Performance Allegations - Encompass Health owns 34 facilities that Medicare rated as having statistically significantly worse rates of potentially preventable readmissions [2]. - The article highlighted alarming mistakes that have led to patient fatalities in Encompass-owned facilities [2].

Core Viewpoint - Levi & Korsinsky has initiated an investigation into Gartner, Inc. regarding potential violations of federal securities laws, particularly focusing on the company's financial disclosures and the prominence of various financial metrics in their communications [1][3]. Financial Performance - Gartner's fourth quarter earnings release on February 3, 2026, highlighted an earnings-per-share (EPS) beat compared to analyst estimates, but also revealed that revenue fell short of consensus expectations and projected a year-over-year decline for the full year 2026 [3]. - The company had previously guided investors to expect an adjusted EPS of at least $12.65 for 2025, based on 78 million shares and anticipated stock repurchases to offset dilution [4]. Stock Market Reaction - Following the earnings release, Gartner's shares dropped over 20% during midday trading, reaching a new 52-week low below $160, with trading volume significantly exceeding normal levels [5].

Core Viewpoint - Distribution Solutions Group, Inc. (DSG) is under investigation for potential violations of federal securities laws following its recent financial disclosures and statements regarding tariff impacts [1][2]. Financial Performance - DSG announced its full year and fourth quarter 2025 financial results on March 5, 2026, indicating challenges faced during the year [2]. - CEO Bryan King acknowledged that DSG navigated "challenging headwinds" in 2025, particularly those related to fluid tariffs [2]. Management Statements - CFO Ron Knutson previously indicated at a November 18, 2025 conference that DSG could "plan around" the impact of tariffs, suggesting a more optimistic outlook at that time [2]. - The contrast between the CEO's and CFO's statements raises questions about the company's preparedness for tariff-related challenges [2]. Legal Context - Lowey Dannenberg P.C. is investigating DSG for potential securities law violations, indicating that there may be significant legal implications for the company [1][3].

Core Viewpoint - Figma Inc. is under investigation for potential violations of federal securities laws following a significant decline in its stock price since its IPO [1][2]. Company Overview - Figma went public on July 31, 2025, with an initial public offering (IPO) price of $33 per share, raising over $1.2 billion by selling nearly 37 million shares [2]. - The company's stock has experienced a notable decline since its debut, leading to potential losses for investors who purchased shares during or traceable to the IPO [2]. Legal Implications - Investors who acquired Figma shares during the IPO and suffered losses may have legal rights under securities laws, which protect against materially misleading statements or omissions in registration statements [3]. - The law firm Lowey Dannenberg P.C. is encouraging affected investors to contact legal counsel to discuss their rights and potential recovery options [3]. Firm Background - Lowey Dannenberg is a national law firm that represents institutional and individual investors who have suffered financial losses due to corporate fraud and violations of federal securities and antitrust laws [5]. - The firm has a strong track record in prosecuting multi-million-dollar lawsuits and has previously recovered billions for investors [5].

Core Viewpoint - Nutex Health, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price after the release of its financial results for Q4 and full-year 2025 [1][2]. Financial Performance - Nutex Health's shares fell over 24% in pre-market trading on March 6, 2026, after reporting a one-time cumulative true-up of $55.0 million related to 18,950 arbitration claims deemed ineligible under the Independent Dispute Resolution (IDR) process [2]. Legal Investigation - Lowey Dannenberg P.C. is investigating Nutex Health for potential securities law violations, particularly concerning the financial losses suffered by investors [1][3]. - Investors who incurred losses exceeding $50,000 in Nutex securities are encouraged to participate in the investigation [2].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. Group 3: Stock Performance and Financial Results - Wealthfront's stock experienced a significant drop following the release of its first quarterly results as a public company on January 12, 2026, which reported net deposit outflows of $208 million, a stark contrast to the $874 million inflows from the same period the previous year [4]. - The stock price fell by $2.12 per share, nearly 17%, from $12.59 on January 12, 2026, to $10.47 on January 13, 2026, following the earnings call where CEO David Fortunato discussed the company's challenges and his personal stake in the home-lending business [4].